These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

879 related items for PubMed ID: 20709651

  • 21. Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for wild-type KRAS metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines.
    Shitara K, Yuki S, Yoshida M, Takahari D, Utsunomiya S, Yokota T, Sato Y, Inaba Y, Tajika M, Kawai H, Yamaura H, Kato M, Yamazaki K, Komatsu Y, Muro K.
    Invest New Drugs; 2012 Apr; 30(2):787-93. PubMed ID: 21174225
    [Abstract] [Full Text] [Related]

  • 22. Cost-effectiveness of targeted therapy with cetuximab in patients with K-ras wild-type colorectal cancer presenting with initially unresectable metastases limited to the liver in a German setting.
    Asseburg C, Frank M, Köhne CH, Hartmann JT, Griebsch I, Mohr A, Osowski U, Schulten J, Mittendorf T.
    Clin Ther; 2011 Apr; 33(4):482-97. PubMed ID: 21635994
    [Abstract] [Full Text] [Related]

  • 23. Bevacizumab plus FOLFIRI or FOLFOX as third-line or later treatment in patients with metastatic colorectal cancer after failure of 5-fluorouracil, irinotecan, and oxaliplatin: a retrospective analysis.
    Kang BW, Kim TW, Lee JL, Ryu MH, Chang HM, Yu CS, Kim JC, Kim JH, Kang YK, Lee JS.
    Med Oncol; 2009 Apr; 26(1):32-7. PubMed ID: 18498064
    [Abstract] [Full Text] [Related]

  • 24. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial.
    Maughan TS, Adams RA, Smith CG, Meade AM, Seymour MT, Wilson RH, Idziaszczyk S, Harris R, Fisher D, Kenny SL, Kay E, Mitchell JK, Madi A, Jasani B, James MD, Bridgewater J, Kennedy MJ, Claes B, Lambrechts D, Kaplan R, Cheadle JP, MRC COIN Trial Investigators.
    Lancet; 2011 Jun 18; 377(9783):2103-14. PubMed ID: 21641636
    [Abstract] [Full Text] [Related]

  • 25. Detection of KRAS oncogene in peripheral blood as a predictor of the response to cetuximab plus chemotherapy in patients with metastatic colorectal cancer.
    Yen LC, Yeh YS, Chen CW, Wang HM, Tsai HL, Lu CY, Chang YT, Chu KS, Lin SR, Wang JY.
    Clin Cancer Res; 2009 Jul 01; 15(13):4508-13. PubMed ID: 19549774
    [Abstract] [Full Text] [Related]

  • 26. SPIRITT: A Randomized, Multicenter, Phase II Study of Panitumumab with FOLFIRI and Bevacizumab with FOLFIRI as Second-Line Treatment in Patients with Unresectable Wild Type KRAS Metastatic Colorectal Cancer.
    Hecht JR, Cohn A, Dakhil S, Saleh M, Piperdi B, Cline-Burkhardt M, Tian Y, Go WY.
    Clin Colorectal Cancer; 2015 Jun 01; 14(2):72-80. PubMed ID: 25982297
    [Abstract] [Full Text] [Related]

  • 27. [Biotherapy in colorectal cancer].
    Des Guetz G.
    J Chir (Paris); 2005 Jun 01; 142(5):291-6. PubMed ID: 16292207
    [Abstract] [Full Text] [Related]

  • 28. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.
    Peeters M, Price TJ, Cervantes A, Sobrero AF, Ducreux M, Hotko Y, André T, Chan E, Lordick F, Punt CJ, Strickland AH, Wilson G, Ciuleanu TE, Roman L, Van Cutsem E, Tzekova V, Collins S, Oliner KS, Rong A, Gansert J.
    J Clin Oncol; 2010 Nov 01; 28(31):4706-13. PubMed ID: 20921462
    [Abstract] [Full Text] [Related]

  • 29. Dose escalating study of cetuximab and 5-FU/folinic acid (FA)/oxaliplatin/irinotecan (FOLFOXIRI) in first line therapy of patients with metastatic colorectal cancer.
    Folprecht G, Hamann S, Schütte K, Trarbach T, Stoehlmacher-Williams J, Ehninger G.
    BMC Cancer; 2014 Jul 19; 14():521. PubMed ID: 25038824
    [Abstract] [Full Text] [Related]

  • 30. Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial.
    Seymour MT, Brown SR, Middleton G, Maughan T, Richman S, Gwyther S, Lowe C, Seligmann JF, Wadsley J, Maisey N, Chau I, Hill M, Dawson L, Falk S, O'Callaghan A, Benstead K, Chambers P, Oliver A, Marshall H, Napp V, Quirke P.
    Lancet Oncol; 2013 Jul 19; 14(8):749-59. PubMed ID: 23725851
    [Abstract] [Full Text] [Related]

  • 31. A phase II trial of FOLFOX6 and cetuximab in the first-line treatment of patients with metastatic colorectal cancer.
    Boccia RV, Cosgriff TM, Headley DL, Badarinath S, Dakhil SR.
    Clin Colorectal Cancer; 2010 Apr 19; 9(2):102-7. PubMed ID: 20378504
    [Abstract] [Full Text] [Related]

  • 32. Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer.
    Van Cutsem E, Lenz HJ, Köhne CH, Heinemann V, Tejpar S, Melezínek I, Beier F, Stroh C, Rougier P, van Krieken JH, Ciardiello F.
    J Clin Oncol; 2015 Mar 01; 33(7):692-700. PubMed ID: 25605843
    [Abstract] [Full Text] [Related]

  • 33. No survival benefit from adding cetuximab or panitumumab to oxaliplatin-based chemotherapy in the first-line treatment of metastatic colorectal cancer in KRAS wild type patients: a meta-analysis.
    Zhou SW, Huang YY, Wei Y, Jiang ZM, Zhang YD, Yang Q, Xie DR.
    PLoS One; 2012 Mar 01; 7(11):e50925. PubMed ID: 23226426
    [Abstract] [Full Text] [Related]

  • 34. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer.
    Bokemeyer C, Bondarenko I, Makhson A, Hartmann JT, Aparicio J, de Braud F, Donea S, Ludwig H, Schuch G, Stroh C, Loos AH, Zubel A, Koralewski P.
    J Clin Oncol; 2009 Feb 10; 27(5):663-71. PubMed ID: 19114683
    [Abstract] [Full Text] [Related]

  • 35. FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO).
    Fornaro L, Lonardi S, Masi G, Loupakis F, Bergamo F, Salvatore L, Cremolini C, Schirripa M, Vivaldi C, Aprile G, Zaniboni A, Bracarda S, Fontanini G, Sensi E, Lupi C, Morvillo M, Zagonel V, Falcone A.
    Ann Oncol; 2013 Aug 10; 24(8):2062-7. PubMed ID: 23666916
    [Abstract] [Full Text] [Related]

  • 36. The evolving role of monoclonal antibodies in colorectal cancer: early presumptions and impact on clinical trial development.
    Eng C.
    Oncologist; 2010 Aug 10; 15(1):73-84. PubMed ID: 20067946
    [Abstract] [Full Text] [Related]

  • 37. A randomized, placebo-controlled phase 2 study of ganitumab or conatumumab in combination with FOLFIRI for second-line treatment of mutant KRAS metastatic colorectal cancer.
    Cohn AL, Tabernero J, Maurel J, Nowara E, Sastre J, Chuah BYS, Kopp MV, Sakaeva DD, Mitchell EP, Dubey S, Suzuki S, Hei YJ, Galimi F, McCaffery I, Pan Y, Loberg R, Cottrell S, Choo SP.
    Ann Oncol; 2013 Jul 10; 24(7):1777-1785. PubMed ID: 23510984
    [Abstract] [Full Text] [Related]

  • 38. Cetuximab plus XELIRI or XELOX for first-line therapy of metastatic colorectal cancer.
    Moosmann N, Heinemann V.
    Clin Colorectal Cancer; 2008 Mar 10; 7(2):110-7. PubMed ID: 18501070
    [Abstract] [Full Text] [Related]

  • 39. Chemotherapy usage patterns in a US-wide cohort of patients with metastatic colorectal cancer.
    Abrams TA, Meyer G, Schrag D, Meyerhardt JA, Moloney J, Fuchs CS.
    J Natl Cancer Inst; 2014 Feb 10; 106(2):djt371. PubMed ID: 24511107
    [Abstract] [Full Text] [Related]

  • 40. Cetuximab plus FOLFOXIRI versus cetuximab plus FOLFOX as conversion regimen in RAS/BRAF wild-type patients with initially unresectable colorectal liver metastases (TRICE trial): A randomized controlled trial.
    Wang DS, Ren C, Li SS, Fong WP, Wu XJ, Xiao J, Li BK, Zheng Y, Ding PR, Chen G, Qiu MZ, Wang ZQ, Wang FH, Luo HY, Wang F, Wang XZ, Wang LY, Xie DJ, Chen T, Li LR, Lu ZH, Zhai XH, Liu TS, Yuan Y, Chen JQ, Tan Q, Pan ZZ, Wan DS, Zhang R, Yuan YF, Xu RH, Li YH.
    PLoS Med; 2024 May 10; 21(5):e1004389. PubMed ID: 38728364
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 44.